ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Schisandrin B targets CD44 to inhibit glioblastoma multiforme.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Glioblastoma multiforme (GBM), the most common malignant primary brain tumor, responds poorly to surgery, radiotherapy, chemotherapy, and immunotherapy, with dismal prognosis and short median survival. There is an urgent need for improved therapies, with supportive and palliative care integral to the multimodal treatment strategy. Traditional Chinese medicine (TCM) exerts antitumor effects via multi-target and multi-pathway mechanisms. Thus, screening and validation of candidate natural small molecules for the therapy and adjuvant therapy of glioblastoma multiforme (GBM) are of great significance. In this study, bioinformatics analysis identified cluster of differentiation 44 (CD44) as a positive correlate of glioblastoma multiforme (GBM). Using cluster of differentiation 44 (CD44) protein structure from the AlphaFold Protein Structure Database, we combined network pharmacology, virtual screening, and molecular docking to pinpoint Schisandrin B (Sch B) as a candidate natural small molecule against glioblastoma multiforme (GBM). In vitro assays verified that Schisandrin B (Sch B) potently inhibited glioblastoma multiforme (GBM) cell proliferation, migration, and invasion. In vivo glioblastoma multiforme (GBM) xenograft models confirmed that Schisandrin B (Sch B) reduced tumor volume, improved mouse survival, and enhanced autonomous activity. Safety evaluations further demonstrated that Schisandrin B (Sch B) had no adverse effects on mouse body weight, autonomous activity, organ index, or tissue morphology. Taken together, Schisandrin B (Sch B) targets cluster of differentiation 44 (CD44) to inhibit glioblastoma multiforme (GBM), and it has relatively good safety performance. This study can provide a research foundation for the therapy and adjuvant therapy of glioblastoma multiforme (GBM).
Indexed as
Identifiers
41765945What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.